Med-IQ

Earn CME/CE

Evidence-Based Treatment for Patients With HCV: Developing Physician Assistant and Nurse Practitioner Experts
E-Publication E-Publication

Evidence-Based Treatment for Patients With HCV: Developing Physician Assistant and Nurse Practitioner Experts


Presented by the AGA Institute and Med-IQ.

Duke MedicineMed-IQ

Time to Complete:
45 minutes
Released:
9/23/16
Expires:
9/22/17

Maximum Credits:

0.75 AMA PRA Category 1 Credit(s)
0.75 American Association of Nurse Practitioners (AANP)

E-Publication E-Publication
Time to Complete:
45 minutes

Released:
9/23/16

Expires:
9/22/17

Maximum Credits:
0.75 AMA PRA Category 1 Credit(s)
0.75 American Association of Nurse Practitioners (AANP)
Share on:
E-Publication E-Publication

Share on:


Time to Complete:
45 minutes
Released:
9/23/16
Expires:
9/22/17


Maximum Credits:
0.75 AMA PRA Category 1 Credit(s)
0.75 American Association of Nurse Practitioners (AANP)


Overview: This CME/CE-certified, interactive publication explores available clinical evidence and guideline recommendations for the management of patients with chronic hepatitis C virus, including the efficacy, safety, and limitations of currently available therapies. It also features video clips of faculty experts discussing how they integrate clinical evidence into their own practice.

Faculty

April G. Morris, NP

Liver Institute of Virginia

Richmond, VA

Gina Storrs, RN, CNP

Certified Adult Nurse Practitioner

Minnesota Gastroenterology PA

St. Paul, MN

Paul Kwo, MD

Professor of Medicine

Chief of Hepatology

Stanford University

Stanford, CA


Disclosure Policy

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.


Disclosure Statement

The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.  

April G. Morris, NP
Consulting fees/advisory boards: AbbVie Inc., Bristol-Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc.
 
Gina Storrs, RN, CNP
Consulting fees/advisory boards: AbbVie Inc., Gilead Sciences, Inc., Merck & Co., Inc.

Paul Kwo, MD
Consulting fees/advisory boards: Abbott Laboratories, AbbVie Inc., Alnylam Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc.
Fees received for promotional/non-CME activities: Innovia
Contracted research: AbbVie Inc., Bristol-Myers Squibb, Conatus Pharmaceuticals Inc., Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc.

The writer, peer reviewers, and activity planners have no financial relationships to disclose.


This activity has been approved for AMA PRA Category 1 Credit™.


This activity is supported by educational grants from AbbVie and Gilead Sciences, Inc.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Share With Patients

Patient TalkPoints Share this education by visiting Patient TalkPoints, where patients can learn more about HCV treatment

VIEW TODAY

Note: This material is not CME certified and, therefore, does not offer any CME/CE credit.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or e-mail info@med-iq.com. For technical assistance, please refer to our support manual.